Stock DNA
Pharmaceuticals: Major
CAD 127 Million (Micro Cap)
NA (Loss Making)
NA
0.00%
-1.15
-26.19%
2.13
Revenue and Profits:
Net Sales:
4 Million
(Quarterly Results - Mar 2025)
Net Profit:
-3 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-38.42%
0%
-38.42%
6 Months
-59.2%
0%
-59.2%
1 Year
-48.19%
0%
-48.19%
2 Years
0%
0%
0.0%
3 Years
0%
0%
0.0%
4 Years
0%
0%
0.0%
5 Years
0%
0%
0.0%
Alpha Cognition, Inc. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
0
EBIT Growth (5y)
-286.28%
EBIT to Interest (avg)
-10.75
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.15
Sales to Capital Employed (avg)
0
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
2.13
EV to EBIT
-3.57
EV to EBITDA
-3.60
EV to Capital Employed
-6.54
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-26.19%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Sideways
Moving Averages
Bearish (Daily)
KST
Bearish
Dow Theory
Bearish
No Trend
OBV
Bearish
Bearish
Shareholding Snapshot : Dec 2020
Shareholding Compare (%holding) 
Majority shareholders
Non Institution
Domestic Funds
Held in 0 Schemes (0%)
Foreign Institutions
Held by 0 Foreign Institutions (0%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Mar'25 - YoY
Mar'25
Mar'24
Change(%)
Net Sales
4.20
0.00
Operating Profit (PBDIT) excl Other Income
-5.30
-6.00
11.67%
Interest
0.00
0.00
Exceptional Items
1.60
-0.90
277.78%
Consolidate Net Profit
-2.90
-6.70
56.72%
Operating Profit Margin (Excl OI)
-1,258.70%
0.00%
-125.87%
USD in Million.
Net Sales
YoY Growth in quarter ended Mar 2025 is 0.00% vs 0.00% in Mar 2024
Consolidated Net Profit
YoY Growth in quarter ended Mar 2025 is 56.72% vs 0.00% in Mar 2024
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-16.20
-13.10
-23.66%
Interest
0.10
0.10
Exceptional Items
-4.40
-5.50
20.00%
Consolidate Net Profit
-20.10
-18.60
-8.06%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is -8.06% vs -17.72% in Dec 2023
About Alpha Cognition, Inc. 
Alpha Cognition, Inc.
Pharmaceuticals: Major
Crystal Bridge Enterprises Inc is a Canada-based capital pool company. The Company is focused on evaluating business opportunities and completing qualifying transaction.






